

Stuart Jon Spechler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/304004/publications.pdf>

Version: 2024-02-01

155
papers

18,322
citations

26567

56
h-index

12233

133
g-index

209
all docs

209
docs citations

209
times ranked

8332
citing authors

#	ARTICLE	IF	CITATIONS
1	ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2022, 117, 27-56.	0.2	313
2	Spastic secondary contractile patterns identified by FLIP panometry in symptomatic patients with unremarkable high-resolution manometry. Neurogastroenterology and Motility, 2022, 34, e14321.	1.6	2
3	Timing of Resumption of Anticoagulation After Polypectomy and Frequency of Post-procedural Complications: A Post-hoc Analysis. Digestive Diseases and Sciences, 2022, 67, 3210-3219.	1.1	2
4	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clinical Gastroenterology and Hepatology, 2022, 20, 2474-2484.e3.	2.4	57
5	A human Barrett's esophagus organoid system reveals epithelial-mesenchymal plasticity induced by acid and bile salts. American Journal of Physiology - Renal Physiology, 2022, 322, G598-G614.	1.6	5
6	Mechanisms and pathophysiology of Barrett oesophagus. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 605-620.	8.2	11
7	Screening for Barrett's oesophagus: are we looking for the right thing?. Gut, 2021, 70, 1426-1427.	6.1	4
8	Lower esophageal sphincter muscle of patients with achalasia exhibits profound mast cell degranulation. Neurogastroenterology and Motility, 2021, 33, e14055.	1.6	18
9	Mast cell effects on esophageal smooth muscle and their potential role in eosinophilic esophagitis and achalasia. American Journal of Physiology - Renal Physiology, 2021, 320, G319-G327.	1.6	16
10	Advances in Biomarkers for Risk Stratification in Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 105-115.	0.6	3
11	Invited response to letter to the editor by Tustumi et al. Neurogastroenterology and Motility, 2021, 33, e14114.	1.6	0
12	Implications of Recent Revelations from Basic and Clinical Studies of Barrett's Esophagus for Screening and Surveillance Strategies. Foregut, 2021, 1, 86-92.	0.3	0
13	Histologic Study of the Esophagogastric Junction of Organ Donors Reveals Novel Glandular Structures in Normal Esophageal and Gastric Mucosae. Clinical and Translational Gastroenterology, 2021, 12, e00346.	1.3	1
14	IL-13/IL4R α Signaling Increases Tension in Human Circular and Longitudinal Esophageal Smooth Muscle Through Distinct Molecular Pathways: Potential Contribution to Reduced Esophageal Distensibility in EoE. FASEB Journal, 2021, 35, .	0.2	0
15	In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump. Gastroenterology, 2021, 160, 2072-2088.e6.	0.6	22
16	Evaluation and Management of Patients with PPI-Refractory Heartburn. Current Treatment Options in Gastroenterology, 2021, 19, 134-152.	0.3	0
17	Mucosal pathogenesis in gastroesophageal reflux disease. Neurogastroenterology and Motility, 2020, 32, e14022.	1.6	40
18	Maintenance Topical Steroid Therapy in Eosinophilic Esophagitis: Not So Hard to Swallow Any More?. Gastroenterology, 2020, 159, 1653-1655.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Refractory Gastroesophageal Reflux Disease and Functional Heartburn. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 343-359.	0.6	16
20	Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 437-450.	1.0	12
21	In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G464-G478.	1.6	16
22	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. <i>Journal of Gastroenterology</i> , 2019, 54, 837-844.	2.3	15
23	Pathogenesis and Cells of Origin of Barrett's Esophagus. <i>Gastroenterology</i> , 2019, 157, 349-364.e1.	0.6	104
24	Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. <i>New England Journal of Medicine</i> , 2019, 381, 1513-1523.	13.9	178
25	Endoscopic Evaluation of the Esophagus and Endoscopic Ultrasonography of the Esophagus. , 2019, , 85-114.		0
26	Efficacy of Prophylactic Hemoclips in Prevention of Delayed Post-Polypectomy Bleeding in Patients With Large Colonic Polyps. <i>Gastroenterology</i> , 2019, 157, 967-976.e1.	0.6	63
27	Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1089-1097.	1.1	37
28	American Registry of Pathology Expert Opinions: Evaluating Patients with Eosinophilic Esophagitis: Practice Points for Endoscopists and Pathologists. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151418.	0.6	3
29	Proton Pump Inhibitors. <i>Medical Clinics of North America</i> , 2019, 103, 1-14.	1.1	20
30	Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells. <i>Gastroenterology</i> , 2019, 156, 130-144.e10.	0.6	46
31	Unique Clinical Features of Los Angeles Grade D Esophagitis Suggest That Factors Other Than Gastroesophageal Reflux Contribute to its Pathogenesis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 9-14.	1.1	8
32	Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. <i>Gastroenterology and Hepatology</i> , 2019, 15, 111-113.	0.2	2
33	New Eosinophilic Esophagitis Concepts Call for Change in Proton Pump Inhibitor Management Before Diagnostic Endoscopy. <i>Gastroenterology</i> , 2018, 154, 1217-1221.e3.	0.6	24
34	Cardiac Metaplasia: Follow, Treat, or Ignore?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2052-2058.	1.1	16
35	Management Options for Patients With GERD and Persistent Symptoms on Proton Pump Inhibitors: Recommendations From an Expert Panel. <i>American Journal of Gastroenterology</i> , 2018, 113, 980-986.	0.2	78
36	Obtaining adequate lamina propria for subepithelial fibrosis evaluation in pediatric eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1207-1214.e3.	0.5	25

#	ARTICLE	IF	CITATIONS
37	Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 617-623.	0.9	31
38	A new candidate for the progenitor cell of Barrett metaplasia. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 7-8.	8.2	3
39	New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?. <i>Gastroenterology</i> , 2018, 154, 1594-1601.	0.6	39
40	Can Eosinophilic Esophagitis Cause Achalasia and Other Esophageal Motility Disorders?. <i>American Journal of Gastroenterology</i> , 2018, 113, 1594-1599.	0.2	61
41	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	0.6	712
42	Speculation as to why the Frequency of Eosinophilic Esophagitis Is Increasing. <i>Current Gastroenterology Reports</i> , 2018, 20, 26.	1.1	17
43	Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 389-404.	2.3	15
44	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1471-1474.	2.4	20
45	Hypoxia-inducible factor-2 β plays a role in mediating oesophagitis in GORD. <i>Gut</i> , 2017, 66, 1542-1554.	6.1	41
46	A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin. <i>American Journal of Gastroenterology</i> , 2017, 112, 734-739.	0.2	39
47	Clarifying misunderstandings and misinterpretations about proton pump inhibitor-responsive oesophageal eosinophilia. <i>Gut</i> , 2017, 66, 1173-1174.	6.1	3
48	Barrett's metaplasia develops from cellular reprogramming of esophageal squamous epithelium due to gastroesophageal reflux. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G615-G622.	1.6	28
49	White Paper AGA: Drug Development for Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1173-1183.	2.4	37
50	The Durability of Antireflux Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 913.	3.8	8
51	Of Mice and Men and Metaplasia. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 4, 183-184.	2.3	2
52	A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2 β : a potential role for targeting HIF-2 β to prevent and treat reflux esophagitis. <i>Current Opinion in Pharmacology</i> , 2017, 37, 93-99.	1.7	39
53	Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2104.	3.8	190
54	NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 439-453.	2.3	43

#	ARTICLE	IF	CITATIONS
55	In oesophageal squamous cells, nitric oxide causes S-nitrosylation of Akt and blocks SOX2 (sex) Tj ETQq1 1 0.784314 rgBT /Overlock 10	6.1	22
56	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. <i>Gut</i> , 2016, 65, 524-531.	6.1	279
57	JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. <i>PLoS ONE</i> , 2016, 11, e0157376.	1.1	54
58	The Effect of Proton Pump Inhibitors on Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 415-424.	1.0	20
59	Mitochondrial STAT3 contributes to transformation of Barrett's epithelial cells that express oncogenic Ras in a p53-independent fashion. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G146-G161.	1.6	18
60	Diagnosis of Esophageal Motility Disorders: Esophageal Pressure Topography vs. Conventional Line Tracing. <i>American Journal of Gastroenterology</i> , 2015, 110, 967-977.	0.2	90
61	543 Support for Wound Healing As the Mechanism for Columnar Metaplasia of the Esophagus in a Rodent Model of Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, S-109.	0.6	1
62	Cardiac mucosa: the heart of the problem. <i>Gut</i> , 2015, 64, 1673-1674.	6.1	7
63	Does Barrett's Esophagus Regress after Surgery (or Proton Pump Inhibitors). <i>Digestive Diseases</i> , 2014, 32, 156-163.	0.8	17
64	Development and Characterization of a Surgical Mouse Model of Reflux Esophagitis and Barrett's Esophagus. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 234-241.	0.9	18
65	Autocrine VEGF Signaling Promotes Proliferation of Neoplastic Barrett's Epithelial Cells Through a PLC-Dependent Pathway. <i>Gastroenterology</i> , 2014, 146, 461-472.e6.	0.6	45
66	In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G129-G139.	1.6	53
67	Use of Hemoclips and Other Measures to Prevent Bleeding During Colonoscopy by Gastroenterologists in Veterans Affairs Hospitals. <i>American Journal of Gastroenterology</i> , 2014, 109, 288-290.	0.2	6
68	Barrett's Esophagus. <i>New England Journal of Medicine</i> , 2014, 371, 836-845.	13.9	432
69	Use of proton pump inhibitors and subsequent risk of celiac disease. <i>Digestive and Liver Disease</i> , 2014, 46, 36-40.	0.4	53
70	Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 243-256.	1.0	48
71	In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor- κ B and activator protein-1. <i>Gut</i> , 2014, 63, 1042-1052.	6.1	62
72	Controversies in Barrett Esophagus. <i>Mayo Clinic Proceedings</i> , 2014, 89, 973-984.	1.4	18

#	ARTICLE	IF	CITATIONS
73	Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. <i>Journal of Clinical Investigation</i> , 2014, 124, 3767-3780.	3.9	81
74	Proton Pump Inhibitors Decrease Eotaxin-3 Expression in the Proximal Esophagus of Children with Esophageal Eosinophilia. <i>PLoS ONE</i> , 2014, 9, e101391.	1.1	42
75	Barrett Esophagus and Risk of Esophageal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 627.	3.8	240
76	Barrett's Esophagus: The American Perspective. <i>Digestive Diseases</i> , 2013, 31, 10-16.	0.8	13
77	Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. <i>Gut</i> , 2013, 62, 824-832.	6.1	286
78	Barrett's Esophagus. , 2013, , 723-738.		5
79	Endoscopic Evaluation of the Esophagus. , 2013, , 101-111.		0
80	Tissue remodeling in eosinophilic esophagitis. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G1175-G1187.	1.6	98
81	Barrett's Esophagus: Is the Goblet Half Empty?. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1237-1238.	2.4	17
82	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. <i>Gastroenterology</i> , 2012, 143, 336-346.	0.6	365
83	Omeprazole Blocks STAT6 Binding to the Eotaxin-3 Promoter in Eosinophilic Esophagitis Cells. <i>PLoS ONE</i> , 2012, 7, e50037.	1.1	203
84	Relationship of Eosinophilic Esophagitis to Gastroesophageal Reflux. , 2012, , 135-146.		0
85	Barrett's Esophagus: Clinical Issues. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 1-7.	0.6	10
86	American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 140, 1084-1091.	0.6	909
87	American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 140, e18-e52.	0.6	968
88	Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. <i>Gastroenterology</i> , 2011, 141, 460-468.	0.6	432
89	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	1.5	1,839
90	Barrett's Esophagus Without Dysplasia: Wait or Ablate?. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1926-1928.	1.1	10

#	ARTICLE	IF	CITATIONS
91	Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF- κ B activation in benign Barrett's epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G278-G286.	1.6	110
92	Buried Metaplasia After Endoscopic Ablation of Barrett's Esophagus: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2011, 106, 1899-1908.	0.2	162
93	Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G454-G460.	1.6	62
94	A Systematic Review of the Risk of Perforation During Esophageal Dilatation for Patients with Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1512-1515.	1.1	95
95	History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus. <i>Gastroenterology</i> , 2010, 138, 854-869.	0.6	181
96	Nanofabricated Sensing Electrodes in a Batteryless Endoluminal Sensing Telemeter for Diagnosis of Gastroesophageal Reflux Disease (GERD). , 2010, , .		0
97	Might the Use of Acid-Suppressive Medications Predispose to the Development of Eosinophilic Esophagitis?. <i>American Journal of Gastroenterology</i> , 2009, 104, 1897-1902.	0.2	90
98	Management of Nondysplastic Barrett's Esophagus: Where Are We Now?. <i>American Journal of Gastroenterology</i> , 2009, 104, 805-808.	0.2	24
99	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. <i>New England Journal of Medicine</i> , 2009, 360, 2277-2288.	13.9	1,348
100	In Benign Barrett's Epithelial Cells, Acid Exposure Generates Reactive Oxygen Species That Cause DNA Double-Strand Breaks. <i>Cancer Research</i> , 2009, 69, 9083-9089.	0.4	89
101	Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical Implications. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2312-2317.	1.1	275
102	Gastroesophageal Reflux Might Cause Esophagitis Through a Cytokine-Mediated Mechanism Rather Than Caustic Acid Injury. <i>Gastroenterology</i> , 2009, 137, 1776-1784.	0.6	327
103	Surgery for Gastroesophageal Reflux Disease: Esophageal Impedance to Progress?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1264-1265.	2.4	23
104	Endoscopic Therapy in Barrett's Esophagus: When and How?. <i>Surgical Oncology Clinics of North America</i> , 2009, 18, 509-521.	0.6	8
105	Intestinal Differentiation in Metaplastic, Nongoblet Columnar Epithelium in the Esophagus. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1006-1015.	2.1	156
106	Unlike Esophageal Squamous Cells, Barrett's Epithelial Cells Resist Apoptosis by Activating the Nuclear Factor- κ B Pathway. <i>Cancer Research</i> , 2009, 69, 672-677.	0.4	42
107	Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. <i>Ecological Management and Restoration</i> , 2008, 21, 43-50.	0.2	146
108	Stem cells in Barrett's esophagus: HALOs or horns?. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 41-43.	0.5	16

#	ARTICLE	IF	CITATIONS
109	Integrated Approach to Treatment of Children and Adults With Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2008, 18, 195-217.	0.6	34
110	Acid, Bile, and CDX: the ABCs of making Barrett's metaplasia. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G211-G218.	1.6	167
111	Thoughts on the Complex Relationship Between Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2007, 102, 1301-1306.	0.2	328
112	Banding Without Resection (Endoscopic Mucosal Ligation) as a Novel Approach for the Ablation of Short-Segment Barrett's Epithelium: Results of a Pilot Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 1640-1645.	0.2	13
113	GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G19-G24.	1.6	17
114	Screening and surveillance for Barrett's esophagus—an unresolved dilemma. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 470-471.	1.7	25
115	Screening and surveillance for Barrett's esophagus. <i>Current GERD Reports</i> , 2007, 1, 179-184.	0.1	1
116	High-Frequency Probe Ultrasonography Has Limited Accuracy for Detecting Invasive Adenocarcinoma in Patients with Barrett's Esophagus and High-Grade Dysplasia or Intramucosal Carcinoma: A Case Series. <i>American Journal of Gastroenterology</i> , 2006, 101, 1773-1779.	0.2	51
117	Thermal Ablation of Barrett's Esophagus: A Heated Debate. <i>American Journal of Gastroenterology</i> , 2006, 101, 1770-1772.	0.2	25
118	Gastric and Esophageal pH in Patients With Barrett's Esophagus Treated With Three Esomeprazole Dosages: A Randomized, Double-Blind, Crossover Trial. <i>American Journal of Gastroenterology</i> , 2006, 101, 1964-1971.	0.2	66
119	Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach. <i>Ca-A Cancer Journal for Clinicians</i> , 2005, 55, 334-351.	157.7	77
120	Barrett's esophagus: A molecular perspective. <i>Current Gastroenterology Reports</i> , 2005, 7, 177-181.	1.1	16
121	Risk of community-acquired pneumonia after acid-suppressive drugs. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 72-73.	1.7	2
122	Fundoplication and the Risk of Esophageal Cancer in Gastroesophageal Reflux Disease: A Veterans Affairs Cohort Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 1002-1008.	0.2	80
123	Dysplasia in Barrett's Esophagus: Limitations of Current Management Strategies. <i>American Journal of Gastroenterology</i> , 2005, 100, 927-935.	0.2	111
124	Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G743-G748.	1.6	64
125	What is the long-term effect of high-dose versus standard-dose omeprazole in patients with dyspepsia?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2004, 1, 12-13.	1.7	0
126	Re-examination of the Cost-Effectiveness of Surgical Versus Medical Therapy in Patients With Gastroesophageal Reflux Disease: The Value of Long-Term Data Collection. <i>American Journal of Gastroenterology</i> , 2004, 99, 1023-1028.	0.2	38

#	ARTICLE	IF	CITATIONS
127	The Management of Patients Who Have "Failed" Antireflux Surgery. American Journal of Gastroenterology, 2004, 99, 552-561.	0.2	62
128	Intestinal metaplasia at the gastroesophageal junction. Gastroenterology, 2004, 126, 567-575.	0.6	68
129	<i>A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop 1</i> 1 Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz J. Gastroenterology, 2004, 127, 310-330.	0.6	579
130	Esophageal complications of gastroesophageal reflux disease: Presentation, diagnosis, management, and outcomes. Clinical Cornerstone, 2003, 5, 41-48.	1.0	18
131	Medical or invasive therapy for GERD: An acidulous analysis. Clinical Gastroenterology and Hepatology, 2003, 1, 81-88.	2.4	8
132	A 59-Year-Old Woman With Gastroesophageal Reflux Disease and Barrett Esophagus. JAMA - Journal of the American Medical Association, 2003, 289, 466.	3.8	6
133	Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers. American Journal of Gastroenterology, 2003, 98, 759-762.	0.2	28
134	Managing Barrett's oesophagus. BMJ: British Medical Journal, 2003, 326, 892-894.	2.4	25
135	The Natural History of Dysplasia and Cancer in Esophagitis and Barrett Esophagus. Journal of Clinical Gastroenterology, 2003, 36, S2-S5.	1.1	29
136	Clinical Manifestations and Esophageal Complications of GERD. American Journal of the Medical Sciences, 2003, 326, 279-284.	0.4	33
137	Barrett's Esophagus. New England Journal of Medicine, 2002, 346, 836-842.	13.9	571
138	Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology, 2002, 122, 299-307.	0.6	196
139	Barrett's esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Medical Clinics of North America, 2002, 86, 1423-1445.	1.1	62
140	Hallmarks of cancer progression in Barrett's oesophagus. Lancet, The, 2002, 360, 1587-1589.	6.3	141
141	Columnar-lined esophagus: Definitions. Chest Surgery Clinics of North America, 2002, 12, 1-13.	0.8	21
142	Disputing dysplasia. Gastroenterology, 2001, 120, 1864-1868.	0.6	35
143	Long-term Outcome of Medical and Surgical Therapies for Gastroesophageal Reflux Disease. JAMA - Journal of the American Medical Association, 2001, 285, 2331.	3.8	817
144	The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology, 1999, 117, 218-228.	0.6	161

#	ARTICLE	IF	CITATIONS
145	AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. <i>Gastroenterology</i> , 1999, 117, 233-254.	0.6	182
146	The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. <i>Gut</i> , 1997, 41, 710-711.	6.1	33
147	Prevalence and Significance of Pancreatic Acinar Metaplasia at the Gastroesophageal Junction. <i>American Journal of Surgical Pathology</i> , 1996, 20, 1507-1510.	2.1	79
148	Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. <i>Contemporary Clinical Trials</i> , 1994, 15, 335-348.	2.0	40
149	Diagnostic inconsistencies in Barrett's esophagus. <i>Gastroenterology</i> , 1994, 107, 945-949.	0.6	158
150	Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. <i>Digestive Diseases and Sciences</i> , 1993, 38, 97-108.	1.1	85
151	Laser photoablation of Barrett's epithelium: Burning issues about burning tissues. <i>Gastroenterology</i> , 1993, 104, 1855-1858.	0.6	24
152	Comparison of Medical and Surgical Therapy for Complicated Gastroesophageal Reflux Disease in Veterans. <i>New England Journal of Medicine</i> , 1992, 326, 786-792.	13.9	561
153	Barrett's Esophagus. <i>New England Journal of Medicine</i> , 1986, 315, 362-371.	13.9	740
154	Barrett Esophagus and Esophageal Adenocarcinoma. , 0, , 826-848.		2
155	Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. <i>Gut</i> , 0, , gutjnl-2022-327281.	6.1	13